Epocrates, Inc., an
) subsidiary, has launched a new application (app) -- Epocrates
Provider Directory - through which its services can be availed at
one place. This positive news is expected to boost investor
confidence in the stock. The company's stock returned an
impressive 32.0% to its investors on a year-to-date basis.
ATHENAHEALTH IN (ATHN): Free Stock Analysis
BIO-RAD LABS -A (BIO): Free Stock Analysis
INSYS THERAP (INSY): Free Stock Analysis
RESMED INC (RMD): Free Stock Analysis Report
To read this article on Zacks.com click here.
This app enables its healthcare professional members to easily
identify colleagues for consultations and patient referrals,
without having to search through the Internet. The unique
Provider Directory app is superior to conventional Epocrates
offerings, as it now helps members to actually communicate with
each other, rather than simply build a one-to-one relationship.
The Epocrates Provider Directory has a large registry of above
700,000 clinicians gathered from public sources. Members using
Epocrates Rx or Epocrates Essentials can easily search for
valuable drug information such as dosing, pricing and black box
warnings, or clinical information such as labs and differential
diagnoses. Moreover, clinicians can edit their own profiles at
any time to ensure continual accuracy.
Management believes that the new mobile tool will enhance
clinician efficiency and workflow by providing correct and
requisite information at the point of care. Moreover, Epocrates
facilitates easy sharing of the provider's information to a
colleague or patient via email.
Earlier, Epocrates had launched another mobile app, "Epocrates
Bugs + Drugs," which combined cloud-based clinical data with a
user-friendly mobile interface. The app was designed to locate
local bacterial superbugs (bacteria that are resistant to
antibiotics) and assist physicians to timely prescribe
appropriate antibiotics. The highly acclaimed "Epocrates Bugs +
Drugs" is available for free on iOS 7 devices in the Apple App
Currently, athenahealth has a Zacks Rank #3 (Hold). While we
choose to remain on the sidelines regarding ATHN, other
better-placed medical products stocks that are worth a look
INSYS Therapeutics, Inc.
Bio-Rad Laboratories, Inc.
). All these stocks carry a Zacks Rank #1 (Strong Buy).